Gapping up
In reaction to strong earnings/guidance:
- PUMP +1.8%
Other news:
- IFRX +74.3% (doses first patient in trial investigating IFX-1 in patients with severe COVID-19-induced pneumonia)
- CEMI +32.8% (to launch DPP COVID-19 serological point-of-care test; results in 15 minutes from a simple finger stick)
- MNK +16.2% (Mallinckrodt plc and Novoteris receive clearance from Health Canada to start pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated lung complications)
- VEL +14% (files to delay its 10-K)
- INSG +12.2% (ramping up production of its 4G and 5G MiFi mobile hotspots and other wireless connectivity devices in response to record increases in demand)
- NVAX +8.4% (signs NanoFlu manufacturing agreement with EBS)
- GCI +8.1% (announces business response to COVID-19)
- OII +4.5% (confirms Q1 guidance but is withdrawing its full-year 2020 guidance)
- BP +3.5% (provides COVID-19update)
- VECO +2.9% (reports prelim Q1 revs in-line with consensus)
- FLXN +2.9% (enters into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo for the development and commercialization of ZILRETTA)
- CMTL +2.4% (provides COVID-19 update; withdraws outlook)
- WSO +2% (increases quarterly dividend to $1.775/share from $1.60/share)
Analyst comments:
- ABM +0.8% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)